Developer docs
API playgroundTry for free, no card

Search company profiles

Spectrum Antimicrobials

Full company profile

uuid0002f2l

Namestring
Spectrum Antimicrobials
Legal namestring
Spectrum Antimicrobials, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Spectrum Antimicrobials, Inc. is a privately held pharmaceutical and medical device company founded in 2018 and headquartered in Petaluma, California. The company develops precision chemistries for infection control, built around its proprietary Tri-Ion™ Chemistry platform — a technology derived from screening more than 900 distinct chemistries that converts naturally occurring proteins into antimicrobial agents active against bacteria, viruses, fungi, and spores. Its commercial portfolio includes Spectricept™ Skin and Wound Cleanser (FDA 510(k)-cleared for U.S. prescription and over-the-counter markets) and Spectricept™ Hand Sanitizer (approved for sale within the UK National Health Service hospital system). The company also operates a preclinical drug-candidate pipeline led by SPC-02, a "weaponized protein" therapeutic with claimed efficacy 4,000 times that of conventional HOCl, intended for upper and lower respiratory infections, wound care, and urinary tract infections.

Spectrum manufactures its products in a 14,000 sq. ft. FDA-registered cGMP facility in Petaluma that supports both device production and dedicated R&D. The company generates revenue primarily through sales of FDA-cleared medical devices distributed via direct enterprise sales to U.S. healthcare providers and prescription/OTC channels, alongside B2B sales into the UK NHS. The drug-candidate pipeline remains preclinical and is explicitly not a current revenue source; pricing is not publicly disclosed, with inquiries directed to a sales email and a planned e-commerce channel referenced on the company website.

The company is led by founders Hoji Alimi (Chairman & CEO), Bill Watson (Executive VP of Strategic Business Alliances), Mohammad Esmaeili (VP Engineering & Chemistry R&D), and Stephanie Alimi (Senior Director of Operations). As of the February 2026 SEC filing, Spectrum has raised approximately $26.4 million from 247 accredited investors through an ongoing $35 million Rule 506(c) exempt equity offering. No institutional venture capital or private equity backing is evident in available disclosures, and an estimated $2 million of offering proceeds are earmarked for payments to executive officers, directors, or promoters.

Short descriptiontext

Spectrum Antimicrobials is a private pharmaceutical company developing Tri-Ion™ precision chemistries for infection control. It commercializes FDA-cleared Spectricept™ wound-care and hand-hygiene devices while advancing a preclinical pipeline of antimicrobial drug candidates.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPetaluma, United States
HQ citystring
Petaluma
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial chemistries, infection control products, wound care devices, hypochlorous acid formulations, antimicrobial drug development
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antimicrobial Pharmaceuticals & Medical Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of FDA-cleared medical devices including Spectricept™ Skin and Wound Cleanser (prescription and OTC markets) and Spectricept™ Hand Sanitizer (UK NHS). Products are distributed through direct sales and potentially e-commerce channels.

spectrumantimicrobials.com
2Therapeutic Drug Candidates
TypeOne Time License
Description

Future revenue potential from drug candidates in development for treatment of upper and lower respiratory infections, wound care, and urinary tract infections (UTIs). Products currently in early development stages, not yet approved or commercialized.

spectrumantimicrobials.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Spectricept Rx
Description

Spectricept Skin and Wound Cleanser Rx featuring Tri-Ion Chemistry for wound care and infection control.

spectrumantimicrobials.com
Core offering1 text field

Spectrum Antimicrobials develops and manufactures precision antimicrobial chemistries for the control, prevention, and treatment of infection. Its commercial offering includes FDA-cleared medical devices (Spectricept™ Skin and Wound Cleanser Rx and Spectricept™ Hand Sanitizer) built on the proprietary Tri-Ion™ Chemistry platform, and it is developing proteomics-based drug candidates (SPC-02) targeting respiratory, wound, and urinary tract infections.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 4,000X greater efficacy than conventional HOCl for SPC-02 drug candidate
+3 more records
Product overview1 text field

Spectrum Antimicrobials is a science-driven pharmaceutical company advancing precision chemistries for infection control. The company operates a unified product portfolio built on its proprietary Tri-Ion™ chemistry platform, which includes FDA-cleared medical devices (Spectricept™ Skin and Wound Cleanser Rx) and a pipeline of proteomics-based drug candidates (SPC-02). The Tri-Ion™ technology converts naturally occurring proteins into therapeutic agents effective against antibiotic-resistant bacteria, viruses, fungi, and spores, with demonstrated stability in challenging clinical environments including high-protein and biofilm conditions.

Product and service2 records
1Spectricept™ Skin and Wound Cleanser Rx
CategoryMedical Device / Antimicrobial Skin and Wound Care
Description

FDA-cleared hypochlorous acid-based skin and wound cleanser featuring proprietary Tri-Ion™ Chemistry for infection control in wound care applications; sold through US prescription and OTC markets and available via the company's sales channel.

2Spectricept™ Hand Sanitizer
CategoryMedical Device / Hand Hygiene and Infection Control
Description

Hand sanitizer product utilizing Tri-Ion™ Chemistry for antimicrobial efficacy, approved for sale within the UK National Health Service hospital system for infection control.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spectrum Antimicrobials

Antimicrobial Pharmaceuticals & Medical Devicesspectrumantimicrobials.com

Spectrum Antimicrobials is a private pharmaceutical company developing Tri-Ion™ precision chemistries for infection control. It commercializes FDA-cleared Spectricept™ wound-care and hand-hygiene devices while advancing a preclinical pipeline of antimicrobial drug candidates.

What Spectrum Antimicrobials does

Spectrum Antimicrobials, Inc. is a privately held pharmaceutical and medical device company founded in 2018 and headquartered in Petaluma, California. The company develops precision chemistries for infection control, built around its proprietary Tri-Ion™ Chemistry platform — a technology derived from screening more than 900 distinct chemistries that converts naturally occurring proteins into antimicrobial agents active against bacteria, viruses, fungi, and spores. Its commercial portfolio includes Spectricept™ Skin and Wound Cleanser (FDA 510(k)-cleared for U.S. prescription and over-the-counter markets) and Spectricept™ Hand Sanitizer (approved for sale within the UK National Health Service hospital system). The company also operates a preclinical drug-candidate pipeline led by SPC-02, a "weaponized protein" therapeutic with claimed efficacy 4,000 times that of conventional HOCl, intended for upper and lower respiratory infections, wound care, and urinary tract infections.

Spectrum manufactures its products in a 14,000 sq. ft. FDA-registered cGMP facility in Petaluma that supports both device production and dedicated R&D. The company generates revenue primarily through sales of FDA-cleared medical devices distributed via direct enterprise sales to U.S. healthcare providers and prescription/OTC channels, alongside B2B sales into the UK NHS. The drug-candidate pipeline remains preclinical and is explicitly not a current revenue source; pricing is not publicly disclosed, with inquiries directed to a sales email and a planned e-commerce channel referenced on the company website.

The company is led by founders Hoji Alimi (Chairman & CEO), Bill Watson (Executive VP of Strategic Business Alliances), Mohammad Esmaeili (VP Engineering & Chemistry R&D), and Stephanie Alimi (Senior Director of Operations). As of the February 2026 SEC filing, Spectrum has raised approximately $26.4 million from 247 accredited investors through an ongoing $35 million Rule 506(c) exempt equity offering. No institutional venture capital or private equity backing is evident in available disclosures, and an estimated $2 million of offering proceeds are earmarked for payments to executive officers, directors, or promoters.

Spectrum Antimicrobials firmographics

Firmographics
Name
Spectrum Antimicrobials
Legal name
Spectrum Antimicrobials, Inc.
Website
https://spectrumantimicrobials.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Spectrum Antimicrobials is a private pharmaceutical company developing Tri-Ion™ precision chemistries for infection control. It commercializes FDA-cleared Spectricept™ wound-care and hand-hygiene devices while advancing a preclinical pipeline of antimicrobial drug candidates.
Ownership category
akta.pro rank

Spectrum Antimicrobials industry classification

Industry
Product category
Antimicrobial Pharmaceuticals & Medical Devices
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Antimicrobial chemistries
  • Infection control products
  • Wound care devices
  • Hypochlorous acid formulations
  • Antimicrobial drug development

Where Spectrum Antimicrobials is headquartered

Location

Headquarters

HQ city
Petaluma
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spectrum Antimicrobials business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Medical Device Sales: Sale of FDA-cleared medical devices including Spectricept™ Skin and Wound Cleanser (prescription and OTC markets) and Spectricept™ Hand Sanitizer (UK NHS). Products are distributed through direct sales and potentially e-commerce channels.
  2. Therapeutic Drug Candidates: Future revenue potential from drug candidates in development for treatment of upper and lower respiratory infections, wound care, and urinary tract infections (UTIs). Products currently in early development stages, not yet approved or commercialized.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Spectrum Antimicrobials product offering

Product offering

Core offering

Spectrum Antimicrobials develops and manufactures precision antimicrobial chemistries for the control, prevention, and treatment of infection. Its commercial offering includes FDA-cleared medical devices (Spectricept™ Skin and Wound Cleanser Rx and Spectricept™ Hand Sanitizer) built on the proprietary Tri-Ion™ Chemistry platform, and it is developing proteomics-based drug candidates (SPC-02) targeting respiratory, wound, and urinary tract infections.

Product overview

Spectrum Antimicrobials is a science-driven pharmaceutical company advancing precision chemistries for infection control. The company operates a unified product portfolio built on its proprietary Tri-Ion™ chemistry platform, which includes FDA-cleared medical devices (Spectricept™ Skin and Wound Cleanser Rx) and a pipeline of proteomics-based drug candidates (SPC-02). The Tri-Ion™ technology converts naturally occurring proteins into therapeutic agents effective against antibiotic-resistant bacteria, viruses, fungi, and spores, with demonstrated stability in challenging clinical environments including high-protein and biofilm conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • Spectricept Rx: Spectricept Skin and Wound Cleanser Rx featuring Tri-Ion Chemistry for wound care and infection control.

Products and services

  • Spectricept™ Skin and Wound Cleanser Rx FDA-cleared hypochlorous acid-based skin and wound cleanser featuring proprietary Tri-Ion™ Chemistry for infection control in wound care applications; sold through US prescription and OTC markets and available via the company's sales channel.
  • Spectricept™ Hand Sanitizer Hand sanitizer product utilizing Tri-Ion™ Chemistry for antimicrobial efficacy, approved for sale within the UK National Health Service hospital system for infection control.

Quantifiable outcome

  • 4,000X greater efficacy than conventional HOCl for SPC-02 drug candidate
  • +3 more outcomes

Companies that use Spectrum Antimicrobials

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Spectrum Antimicrobials technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Spectrum Antimicrobials partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Spectrum Antimicrobials competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Spectrum Antimicrobials social profiles

Digital presence

Spectrum Antimicrobials compliance and trust

Trust signal

Compliance3 records

Spectrum Antimicrobials financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spectrum Antimicrobials leadership team

Management profile

Number of profiles

Profiles10 records

Spectrum Antimicrobials funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spectrum Antimicrobials M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spectrum Antimicrobials

What does Spectrum Antimicrobials do?

Spectrum Antimicrobials develops and manufactures precision antimicrobial chemistries for the control, prevention, and treatment of infection. Its commercial offering includes FDA-cleared medical devices (Spectricept™ Skin and Wound Cleanser Rx and Spectricept™ Hand Sanitizer) built on the proprietary Tri-Ion™ Chemistry platform, and it is developing proteomics-based drug candidates (SPC-02) targeting respiratory, wound, and urinary tract infections.

Is Spectrum Antimicrobials a public or private company?

Spectrum Antimicrobials is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Spectrum Antimicrobials founded?

Spectrum Antimicrobials was founded in 2018. It employs 11 to 50 people.

Where is Spectrum Antimicrobials based?

Spectrum Antimicrobials is headquartered in Petaluma, United States, in the North America region.

How does Spectrum Antimicrobials make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are therapeutic Drug Candidates.

Does Spectrum Antimicrobials have an API?

No public API is recorded for Spectrum Antimicrobials.

What industry is Spectrum Antimicrobials in?

Spectrum Antimicrobials's product category is Antimicrobial Pharmaceuticals & Medical Devices. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DSpectrum Antimicrobials, Inc. filed a Form D with the SEC to register an exempt offering of equity securities under Rule 506(c), aiming to raise up to $35 million. The filing indicates that $13.4 million has been sold to 108 investors since the first sale on March 21, 2020, with Craft Capital Management LLC acting as the associated broker or dealer.SecSEC FORM DSpectrum Antimicrobials, Inc. filed a Form D with the Securities and Exchange Commission for an exempt securities offering under Rule 506(b). The company reports raising $3,855,000 of its $4,000,000 total offering goal from 28 investors since the first sale on July 25, 2022. The filing discloses that approximately $802,395 in gross proceeds is estimated to be used for payments to executive officers, directors, or promoters.SecSEC FORM DSpectrum Antimicrobials, Inc. filed a Form D with the SEC to report an exempt securities offering under Rule 506(c). The company has raised $13,111,475 of its total target offering amount of $35,000,000 from 105 investors since the first sale on March 21, 2020.SecSEC FORM DSpectrum Antimicrobials, Inc. filed a Form D with the SEC to report an exempt offering of securities under Rule 506(c). The company has raised $7.66 million out of a total target of $28.75 million, with 50 investors participating in the equity offering.GlobeNewswireSpectrum Antimicrobials, Inc. Announces the Launch of itsSpectrum Antimicrobials launched Vetricept, a wound care cleanser for animals, in its new Animal Health Division. The product uses a patent-pending hypochlorous acid formula and was donated to UC Davis for wildfire-affected animals. The company plans additional animal health launches in 2021.GlobeNewswireSpectrum Antimicrobials, Inc. Announces Breakthrough DrugSpectrum Antimicrobials announced SPC-069, a novel antiviral drug candidate for treating pulmonary infections caused by viruses, bacteria, and fungi. The company plans to advance it into human clinical studies as soon as possible with a partner or after financing. The drug is a patent-pending modified hypochlorous acid formulation.